☆ 4.2 Article

Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) - Part 2 with Recommendations for the Therapy of Primary, Recurrent and Advanced Breast Cancer

GEBURTSHILFE UND FRAUENHEILKUNDE (2018)

Journal

GEBURTSHILFE UND FRAUENHEILKUNDE

Volume 78, Issue 11, Pages 1056-1088

Publisher

GEORG THIEME VERLAG KG

DOI: 10.1055/a-0646-4630

Keywords

breast cancer; guideline; therapy; primary breast cancer; metastatic breast cancer

Categories

Obstetrics & Gynecology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Abstract

Purpose The aim of this official guideline coordinated and published by the German Society for Gynecology and Obstetrics (DGGG) and the German Cancer Society (DKG) was to optimize the screening, diagnosis, therapy and follow-up care of breast cancer. Method The process of updating the S3 guideline published in 2012 was based on the adaptation of identified source guidelines. They were combined with reviews of evidence compiled using PICO (Patients/Interventions/Control/Outcome) questions and with the results of a systematic search of literature databases followed by the selection and evaluation of the identified literature. The interdisciplinary working groups took the identified materials as their starting point and used them to develop suggestions for recommendations and statements, which were then modified and graded in a structured consensus process procedure. Recommendations Part 2 of this short version of the guideline presents recommendations for the therapy of primary, recurrent and metastatic breast cancer. Loco-regional therapies are de-escalated in the current guideline. In addition to reducing the safety margins for surgical procedures, the guideline also recommends reducing the radicality of axillary surgery. The choice and extent of systemic therapy depends on the respective tumor biology. New substances are becoming available, particularly to treat metastatic breast cancer.

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Article Oncology

Biomarkers for Systemic Therapy in Metastatic Breast Cancer: ASCO Guideline Update

N. Lynn Henry, Mark R. Somerfield, Zoneddy Dayao, Anthony Elias, Kevin Kalinsky, Lisa M. McShane, Beverly Moy, Ben Ho Park, Kelly M. Shanahan, Priyanka Sharma, Rebecca Shatsky, Erica Stringer-Reasor, Melinda Telli, Nicholas C. Turner, Angela DeMichele

Summary: This study aims to update the biomarkers that guide systemic therapy for metastatic breast cancer (MBC). The authors conducted a systematic review and identified 19 studies, providing recommendations for testing and treatment. However, there is insufficient evidence for some tests' eligibility and monitoring methods.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Article Medicine, General & Internal

Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer

A. Bardia, S. A. Hurvitz, S. M. Tolaney, D. Loirat, K. Punie, M. Oliveira, A. Brufsky, S. D. Sardesai, K. Kalinsky, A. B. Zelnak, R. Weaver, T. Traina, F. Dalenc, P. Aftimos, F. Lynce, S. Diab, J. Cortes, J. O'Shaughnessy, V Dieras, C. Ferrario, P. Schmid, L. A. Carey, L. Gianni, M. J. Piccart, S. Loibl, D. M. Goldenberg, Q. Hong, M. S. Olivo, L. M. Itri, H. S. Rugo

Summary: Patients with metastatic triple-negative breast cancer treated with Sacituzumab govitecan had significantly longer progression-free and overall survival compared to standard chemotherapy, but experienced more frequent myelosuppression and diarrhea as adverse events.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Oncology

Treatment of Metastatic Colorectal Cancer: ASCO Guideline

Van K. Morris, Erin B. Kennedy, Nancy N. Baxter, Al B. Benson, Andrea Cercek, May Cho, Kristen K. Ciombor, Chiara Cremolini, Anjee Davis, Dustin A. Deming, Marwan G. Fakih, Sepideh Gholami, Theodore S. Hong, Ishmael Jaiyesimi, Kelsey Klute, Christopher Lieu, Hanna Sanoff, John H. Strickler, Sarah White, Jason A. Willis, Cathy Eng

Summary: The purpose of this study is to develop treatment recommendations for patients with metastatic colorectal cancer (mCRC). An Expert Panel convened by ASCO conducted a systematic review of relevant studies and developed recommendations for clinical practice. Based on the inclusion criteria, five systematic reviews and ten randomized controlled trials were included in the analysis. The recommendations include offering doublet chemotherapy or triplet therapy to previously untreated mCRC patients who are initially unresectable, based on studies of chemotherapy combined with anti-vascular endothelial growth factor antibodies. Pembrolizumab is recommended for first-line treatment of mCRC patients with microsatellite instability-high or deficient mismatch repair tumors. Chemotherapy and anti-epidermal growth factor receptor therapy are recommended for microsatellite stable or proficient mismatch repair left-sided treatment-naive RAS wild-type mCRC, while chemotherapy and anti-vascular endothelial growth factor therapy are recommended for microsatellite stable or proficient mismatch repair RAS wild-type right-sided mCRC. Encorafenib plus cetuximab is recommended for previously treated BRAF V600E-mutant mCRC patients who have progressed after one previous line of therapy. Other recommendations are provided for patients with colorectal peritoneal metastases, liver metastases, and candidates for potentially curative resection of liver metastases. Multidisciplinary team management and shared decision making are also recommended.

JOURNAL OF CLINICAL ONCOLOGY (2023)

Add to Collection

Editorial Material Medicine, Research & Experimental

Immunological barriers to immunotherapy in primary and metastatic breast cancer

Mara De Martino, Claire Vanpouille-Box, Lorenzo Galluzzi

Summary: Research indicates that radiation therapy can enhance the sensitivity of mouse mammary carcinomas to immune checkpoint inhibitors, but clinical trials in breast cancer patients have shown little efficacy. These observations highlight potential immunological barriers that may prevent radiation therapy from unlocking the therapeutic potential of ICIs in patients with breast cancer.

EMBO MOLECULAR MEDICINE (2021)

Add to Collection

Article Oncology

Determinants of Guideline-Discordant Breast Cancer Care

Jean A. McDougall, Linda S. Cook, Mei-Tzu C. Tang, Hannah M. Linden, Beti Thompson, Christopher Li

Summary: This study found that instrumental social support, patient support services, and communication with doctors and their staff were associated with guideline concordance in early-stage breast cancer survivors. These factors could be potential targets for interventions aimed at improving breast cancer care delivery.

CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2021)

Add to Collection

Review Oncology

Updates in endocrine therapy for metastatic breast cancer

Poorni M. Manohar, Nancy E. Davidson

Summary: Endocrine therapy remains the main treatment for hormone receptor-positive, HER2-negative breast cancer, with resistance to hormone therapy driving the development of new drug combinations and expanding treatment options. While incurable, many patients can enjoy years of survival with good quality of life by cycling through various available agents.

CANCER BIOLOGY & MEDICINE (2022)

Add to Collection

Review Oncology

Primary-Site Local Therapy for Patients with De Novo Metastatic Breast Cancer: An Educational Review

Seema Ahsan Khan, Steven Schuetz, Omid Husseini

Summary: The current evidence fails to support the effectiveness of the paradigm guiding the management of de novo metastatic breast cancer.

ANNALS OF SURGICAL ONCOLOGY (2022)

Add to Collection

Article Oncology

Testing for ESR1 Mutations to Guide Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Rapid Recommendation Update

Harold Burstein, Angela R. DeMichele, Mark Somerfield, N. Lynn Henry

Summary: ASCO Rapid Recommendations Updates revise selected ASCO guideline recommendations in response to new and practice-changing data. These updates are based on evidence reviews and follow ASCO's Guideline Methodology Manual. The aim is to promptly disseminate updated recommendations to enhance cancer care decisions for healthcare professionals and the public.

JOURNAL OF CLINICAL ONCOLOGY (2023)

Add to Collection

Article Oncology

Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Guideline Update

Neelima Denduluri, Mark R. Somerfield, Mariana Chavez-MacGregor, Amy H. Comander, Zoneddy Dayao, Andrea Eisen, Rachel A. Freedman, Ragisha Gopalakrishnan, Stephanie L. Graff, Michael J. Hassett, Tari A. King, Gary H. Lyman, Gillian Rice Maupin, Raquel Nunes, Cheryl L. Perkins, Melinda L. Telli, Maureen E. Trudeau, Antonio C. Wolff, Sharon H. Giordano

Summary: The study recommends offering 14 cycles of adjuvant T-DM1 to patients with HER2-positive breast cancer with pathologic invasive residual disease after standard preoperative chemotherapy and HER2-targeted therapy, based on the results of the KATHERINE trial.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection

Article Pharmacology & Pharmacy

SREKA-targeted liposomes for highly metastatic breast cancer therapy

Balazs Vari, Levente Dokus, Adina Borbely, Aniko Gaal, Diana Vari-Mezo, Ivan Randelovic, Anna Solyom-Tisza, Zoltan Varga, Norbert Szoboszlai, Gabor Mezo, Jozsef Tovari

Summary: Chemotherapy remains an important treatment for various types of tumors, but its poor prognosis is often due to metastases. PEGylated liposomes with CREKA targeting moiety have been widely used as therapeutic agents in highly metastatic experimental models. In this study, we designed different liposome formulations with varying amounts of targeting moieties attached to their DSPE-PEG molecules. We also developed a new tumor-homing pentapeptide (SREKA) and a novel conjugation strategy between SREKA and DSPE-PEGs. Our results showed that SREKA-liposomes exhibited similar characteristics and tumor-homing capabilities to CREKA-liposomes, but had higher production yield and better stability upon conjugation. SREKA-liposomes effectively inhibited primary tumor growth, reduced metastasis incidence, and improved the survival rate of tumor-bearing mice. Additionally, the amount of targeting moiety attached to DSPE-PEGs played a crucial role in the stability, toxicity, and targeting of the liposomes.

DRUG DELIVERY (2023)

Add to Collection

Article Oncology

Initial Management of Noncastrate Advanced, Recurrent, or Metastatic Prostate Cancer: ASCO Guideline Update

Katherine S. Virgo, R. Bryan Rumble, Ronald de Wit, David S. Mendelson, Thomas J. Smith, Mary-Ellen Taplin, James L. Wade, Charles L. Bennett, Howard I. Scher, Paul L. Nguyen, Martin Gleave, Scott C. Morgan, Andrew Loblaw, Sean Sachdev, David L. Graham, Neha Vapiwala, Amy M. Sion, Virgil H. Simons, James Talcott

Summary: The updated ASCO guidelines recommend using Docetaxel, abiraterone, enzalutamide, or apalutamide in combination with androgen deprivation therapy (ADT) as standard care for noncastrate metastatic prostate cancer. In locally advanced nonmetastatic prostate cancer patients who have undergone radiotherapy, ADT combined with abiraterone and prednisolone is suggested. The guidelines also provide recommendations for management of biochemically recurrent nonmetastatic prostate cancer.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection

Article Multidisciplinary Sciences

Distinct shared and compartment-enriched oncogenic networks drive primary versus metastatic breast cancer

Zhe Jiang, YoungJun Ju, Amjad Ali, Philip E. D. Chung, Patryk Skowron, Dong-Yu Wang, Mariusz Shrestha, Huiqin Li, Jeff C. Liu, Ioulia Vorobieva, Ronak Ghanbari-Azarnier, Ethel Mwewa, Marianne Koritzinsky, Yaacov Ben-David, James R. Woodgett, Charles M. Perou, Adam Dupuy, Gary D. Bader, Sean E. Egan, Michael D. Taylor, Eldad Zacksenhaus

Summary: Metastatic breast cancer is a major cause of death in women worldwide, and there is still controversy over the relationship between oncogenic drivers for metastasis and primary cancer. Through transposon-mutagenesis screens and loss-of-function Rb experiments in mice, the authors identified gene-centric common insertion sites (gCIS) that are enriched in primary tumors, metastases, or shared by both. Analysis of clinical cohorts revealed similar patterns in human breast cancer, with subtype-specific shared-drivers, primary-enriched, and metastasis-enriched oncogenic signaling. Targeting shared- and metastasis-enriched drivers could be a rational strategy to prevent metastatic breast cancer.

NATURE COMMUNICATIONS (2023)

Add to Collection

Article Oncology

Chemotherapy and Targeted Therapy for Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That Is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline Rapid Recommendation Update

Beverly Moy, Bryan Rumble, Lisa A. Carey

Summary: ASCO Rapid Recommendations Updates aim to disseminate timely updated cancer care options to healthcare practitioners and the public.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Article Oncology

Multilevel predictors of guideline concordant needle biopsy use for non-metastatic breast cancer

Anja Zgodic, Jan M. Eberth, Benjamin D. Smith, Whitney E. Zahnd, Swann A. Adams, Brian P. McKinley, Ronnie D. Horner, Mark A. O'Rourke, Dawn W. Blackhurst, Matthew F. Hudson

Summary: This study examines the factors influencing needle biopsy receipt among women with non-metastatic breast cancer in the United States. It finds that Hispanic and Medicaid patients, as well as those receiving care at Integrated Network Cancer Programs, are more likely to receive needle biopsy. Conversely, non-metropolitan patients, those with early cancer stages, comorbidities, and those receiving care at Community Cancer Programs are less likely to receive needle biopsy. Addressing these disparities in diagnostic practices may help improve outcomes for underserved breast cancer patients.

BREAST CANCER RESEARCH AND TREATMENT (2021)

Add to Collection

Article Oncology

Heterogeneity in Signaling Pathway Activity within Primary and between Primary and Metastatic Breast Cancer

Marcia A. Inda, Paul van Swinderen, Anne van Brussel, Cathy B. Moelans, Wim Verhaegh, Hans van Zon, Eveline den Biezen, Jan Willem Bikker, Paul J. van Diest, Anja van de Stolpe

Summary: Personalized breast cancer treatment with targeted therapy requires identification of responder patients. Phenotypical heterogeneity within the primary tumor and between primary tumor and metastases may affect therapy response, suggesting analysis of metastatic samples for late stage patients is important. Targeted therapy based on analysis of one primary tumor biopsy may not fully represent the heterogeneity within and between tumors, highlighting the need for further analysis of metastatic biopsies.

CANCERS (2021)

Add to Collection

Article Oncology

Real-world experience of metronomic chemotherapy in metastatic breast cancer: results of a retrospective unicenter study

Slavomir Krajnak, Jana Krajnakova, Katharina Anic, Katrin Almstedt, Anne-Sophie Heimes, Valerie Catherine Linz, Amelie Loewe, Mona Wanda Schmidt, Annette Hasenburg, Marcus Schmidt, Marco Johannes Battista

Summary: In this retrospective unicenter study, we demonstrated real-word data on metronomic chemotherapy in metastatic breast cancer (MBC). The results showed that metronomic chemotherapy was effective and well tolerated in MBC patients, suggesting it as a valuable treatment option.

BREAST CARE (2023)

Add to Collection

Article Oncology

CCNE1 and survival of patients with tubo-ovarian high-grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study

Eun-Young Kang, Ashley Weir, Nicola S. Meagher, Kyo Farrington, Gregg S. Nelson, Prafull Ghatage, Cheng-Han Lee, Marjorie J. Riggan, Adelyn Bolithon, Gordana Popovic, Betty Leung, Katrina Tang, Neil Lambie, Joshua Millstein, Jennifer Alsop, Michael S. Anglesio, Beyhan Ataseven, Ellen Barlow, Matthias W. Beckmann, Jessica Berger, Christiani Bisinotto, Hans Boesmueller, Jessica Boros, Alison H. Brand, Angela Brooks-Wilson, Sara Y. Brucker, Michael E. Carney, Yovanni Casablanca, Alicia Cazorla-Jimenez, Paul A. Cohen, Thomas P. Conrads, Linda S. Cook, Penny Coulson, Madeleine Courtney-Brooks, Daniel W. Cramer, Philip Crowe, Julie M. Cunningham, Cezary Cybulski, Kathleen M. Darcy, Mona A. El-Bahrawy, Esther Elishaev, Ramona Erber, Rhonda Farrell, Sian Fereday, Anna Fischer, Maria J. Garcia, Simon A. Gayther, Aleksandra Gentry-Maharaj, C. Blake Gilks, Marcel Grube, Paul R. Harnett, Shariska Petersen Harrington, Philipp Harter, Arndt Hartmann, Jonathan L. Hecht, Sebastian Heikaus, Alexander Hein, Florian Heitz, Joy Hendley, Brenda Y. Hernandez, Susanna Hernando Polo, Sabine Heublein, Akira Hirasawa, Estrid Hogdall, Claus K. Hogdall, Hugo M. Horlings, David G. Huntsman, Tomasz Huzarski, Andrea Jewell, Mercedes Jimenez-Linan, Michael E. Jones, Scott H. Kaufmann, Catherine J. Kennedy, Dineo Khabele, Felix K. F. Kommoss, Roy F. P. M. Kruitwagen, Diether Lambrechts, Nhu D. Le, Marcin Lener, Jenny Lester, Yee Leung, Anna Linder, Liselore Loverix, Jan Lubinski, Rashna Madan, G. Larry Maxwell, Francesmary Modugno, Susan L. Neuhausen, Alexander Olawaiye, Siel Olbrecht, Sandra Orsulic, Jose Palacios, Celeste Leigh Pearce, Malcolm C. Pike, Carmel M. Quinn, Ganendra Raj Mohan, Cristina Rodriguez-Antona, Matthias Ruebner, Andy Ryan, Stuart G. Salfinger, Naoko Sasamoto, Joellen M. Schildkraut, Minouk J. Schoemaker, Mitul Shah, Raghwa Sharma, Yurii B. Shvetsov, Naveena Singh, Gabe S. Sonke, Linda Steele, Colin J. R. Stewart, Karin Sundfeldt, Anthony J. Swerdlow, Aline Talhouk, Adeline Tan, Sarah E. Taylor, Kathryn L. Terry, Aleksandra Toloczko, Nadia Traficante, Koen K. Van de Vijver, Maaike A. van der Aa, Toon Van Gorp, Els Van Nieuwenhuysen, Lilian Van-Wagensveld, Ignace Vergote, Robert A. Vierkant, Chen Wang, Lynne R. Wilkens, Stacey J. Winham, Anna H. Wu, Javier Benitez, Andrew Berchuck, Francisco J. Candido Dos Reis, Anna DeFazio, Peter A. Fasching, Ellen L. Goode, Marc T. Goodman, Jacek Gronwald, Beth Y. Karlan, Stefan Kommoss, Usha Menon, Hans-Peter Sinn, Annette Staebler, James D. Brenton, David D. Bowtell, Paul D. P. Pharoah, Susan J. Ramus, Martin Kobel

Summary: This study validates that high-level amplification of CCNE1 is associated with shorter survival in tubo-ovarian high-grade serous carcinoma (HGSC), supporting its use as a prognostic biomarker in this disease.

CANCER (2023)

Add to Collection

Article Pathology

High-Grade Endometrial Stromal Sarcomas With YWHAE::NUTM2 Gene Fusion Exhibit Recurrent CDKN2A Alterations and Absence of p16 Staining is a Poor Prognostic Marker

Felix K. F. Kommoss, Lisa-Marie Mar, Brooke E. Howitt, Krisztina Hanley, Gulisa Turashvilli, Rolf Buslei, Julie A. Irving, Brendan C. Dickson, Christian Koelsche, Hans-Peter Sinn, Peter Schirmacher, Andreas von Deimling, Sarah Chiang, W. Glenn McCluggage, Sabrina Croce, Colin J. R. Stewart, Cheng-Han Lee

Summary: This study molecularly characterized 36 cases of high-grade endometrial stromal sarcoma (HGESS), and found that these tumors frequently harbor recurrent events involving the CDKN2A locus on chromosome 9p. The study showed that CDKN2A alterations are a cooperative driver of tumorigenesis in a subset of HGESSs with the YWHAE::NUTM2 gene fusion, and that p16 may be a potential prognostic marker.

MODERN PATHOLOGY (2023)

Add to Collection

Article Medicine, General & Internal

Expression of the Immunohistochemical Markers CK5, CD117, and EGFR in Molecular Subtypes of Breast Cancer Correlated with Prognosis

Carla E. Schulmeyer, Peter A. Fasching, Lothar Haeberle, Julia Meyer, Michael Schneider, David Wachter, Matthias Ruebner, Patrik Poeschke, Matthias W. Beckmann, Arndt Hartmann, Ramona Erber, Paul Gass

Summary: The study evaluated the prognosis of patients with triple-negative breast cancer (TNBC) and other subtypes by using a biomarker panel including cytokeratin 5 (CK5), cluster of differentiation 117 (CD117), and epidermal growth factor receptor (EGFR). The results showed that the non-TBN subgroup of TNBC lesions with at least one positive biomarker (CK5, CD117, and/or EGFR) had longer disease-free survival (DFS) and overall survival (OS). This highlights the importance of molecular-based subclassifications of breast cancer for treatment options and prognosis stratification.

DIAGNOSTICS (2023)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

Development and validation of a four-dimensional registration technique for DCE breast MRI

Chiara Mattusch, Ulrich Bick, Florian Michallek

Summary: By objectively and subjectively assessing the impact of PCA-based registration on pretreatment DCE-MRIs of breast cancer patients, the study validates the effectiveness of four-dimensional registration in improving image quality and reducing uncertainty in quantitative perfusion modeling.

INSIGHTS INTO IMAGING (2023)

Add to Collection

Article Endocrinology & Metabolism

Comparing gene expression in deep infiltrating endometriosis with adenomyosis uteri: evidence for dysregulation of oncogene pathways

A. Marshall, K. F. Kommoss, H. Ortmann, M. Kirchner, J. Jauckus, P. Sinn, T. Strowitzki, A. Germeyer

Summary: This study molecularly characterized the gene expression signatures of adenomyosis uteri (FA) and deep infiltrating endometriosis (DIE). The results showed significant differences in RNA expression levels between the two diseases. Genes belonging to the PI3K pathway were highly expressed in DIE, while genes belonging to the RAS pathway were highly expressed in FA.

REPRODUCTIVE BIOLOGY AND ENDOCRINOLOGY (2023)

Add to Collection

Article Medicine, Research & Experimental

PRECYCLE: multicenter, randomized phase IV intergroup trial to evaluate the impact of eHealth-based patient-reported outcome (PRO) assessment on quality of life in patients with hormone receptor positive, HER2 negative locally advanced or metastatic breast cancer treated with palbociclib and an aromatase inhibitor or palbociclib and fulvestrant

Tom Degenhardt, Peter A. Fasching, Diana Lueftner, Volkmar Mueller, Christoph Thomssen, Christian Schem, Isabell Witzel, Thomas Decker, Hans Tesch, Sherko Kuemmel, Christoph Uleer, Rachel Wuerstlein, Oliver Hoffmann, Mathias Warm, Norbert Marschner, Timo Schinkoethe, Ronald E. Kates, Johannes Schumacher, Burkhard Otremba, Matthias Zaiss, Nadia Harbeck, Marcus Schmidt

Summary: This article discusses an important issue in breast cancer treatment, which is medication adherence. The use of an eHealth-based platform to support treatment management and physician-patient interaction can help improve patients' adherence to treatment and quality of life.

TRIALS (2023)

Add to Collection

Article Multidisciplinary Sciences

Circulating cf-miRNA as a more appropriate surrogate liquid biopsy marker than cfDNA for ovarian cancer

Aoife Ward Gahlawat, Tania Witte, Peter Sinn, Sarah Schott

Summary: Ovarian cancer is an aggressive disease with low survival rates. Liquid biopsy markers, specifically cf-miRNAs, show potential as an independent prognostic factor for survival. Upregulation of miR-200c and miR-141 in both plasma and tissues of OC patients correlates with adverse clinical features. cf-miRNAs are more easily obtained and stable in blood, making them a suitable liquid biopsy marker for OC.

SCIENTIFIC REPORTS (2023)

Add to Collection

Article Biochemistry & Molecular Biology

Prognostic Impact of CD38-and IgκC-Positive Tumor-Infiltrating Plasma Cells in Triple-Negative Breast Cancer

Anne-Sophie Heimes, Natali Riedel, Katrin Almstedt, Slavomir Krajnak, Roxana Schwab, Kathrin Stewen, Antje Lebrecht, Marco Johannes Battista, Walburgis Brenner, Annette Hasenburg, Marcus Schmidt

Summary: The higher immunogenicity of triple-negative breast cancer (TNBC) compared to other subtypes is due to its higher mutational load. In this study, the prognostic significance of tumor-infiltrating plasma cells in TNBC patients was analyzed. The expression of CD38 and Ig kappa C markers was used to evaluate the infiltration of plasma cells. It was found that higher tumor infiltration with CD38-positive plasma cells was associated with longer metastasis-free survival. CD38 was identified as an independent prognostic factor. The nodal status also had a significant impact on prognosis. Higher expression of Ig kappa C was associated with a better outcome, although not statistically significant. The study also showed a correlation between plasma cell infiltration and the BRCA mutation status.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Add to Collection

Article Oncology

Incidence and Resolution of Eribulin-Induced Peripheral Neuropathy (IRENE) in Locally Advanced or Metastatic Breast Cancer: Prospective Cohort Study

Hans-Joachim Lueck, Marcus Schmidt, Tobias Hesse, Oliver Hoffmann, Bernhard J. Heinrich, Tjoung-Won Park-Simon, Eva-Maria Grischke, Rudolf Weide, Harald Mueller-Huesmann, Kerstin Luedtke-Heckenkamp, Dorothea Fischer, Cosima Zemlin, Matthias Koegel, Jane Wu, Helga Schmitz, Christian Engelbrecht, Christian Jackisch

Summary: The study assessed the incidence and severity of peripheral neuropathy (PN) in breast cancer patients treated with eribulin. The rates of any grade and grade ≥3 PN observed in this real-world study were consistent with those observed in phase III randomized clinical trials. No new safety findings were observed.

ONCOLOGIST (2023)

Add to Collection

Review Oncology

Endocrine therapy in metastatic breast cancer-more than just CDK4/6 inhibitors

Annika Droste, Marcus Schmidt

Summary: Advanced hormone receptor-positive breast cancer is a common and incurable disease in women. Inhibiting the hormonal growth signals through anti-hormonal therapy offers a potential solution, although drug resistance remains a challenge. Molecularly targeted substances, such as cyclin-dependent kinase inhibitors, improve survival rates and enhance endocrine therapy's effectiveness. Targeting the phosphoinositide 3 kinase/protein kinase B/mammalian target of rapamycin pathway shows promise in overcoming endocrine resistance. Developing new therapies to combat endocrine resistance is an urgent challenge, and this review examines promising approaches.

JOURNAL OF CANCER METASTASIS AND TREATMENT (2023)

Add to Collection

Article Obstetrics & Gynecology

Personalized medicine-from translational research to clinical practice

Marcus Schmidt, Carsten Denkert, Kerstin Rhiem, Thomas Decker, Sibylle Loibl

Summary: This article presents the evidence for personalized therapy of advanced breast cancer and explains the standardized classifications of treatment relevance. The treatment relevance of genomic alterations is assessed by professional societies. Evidence-based personalized medicine can improve the treatment outcomes for metastatic breast cancer patients.

GYNAKOLOGIE (2023)

Add to Collection

Article Obstetrics & Gynecology

A questionnaire-based survey on the diagnostic and therapeutic approaches for patients with STIC in Germany

Josche van der Ven, Valerie Catherine Linz, Katharina Anic, Mona Wanda Schmidt, Amelie Loewe, Slavomir Krajnak, Marcus Schmidt, Stefan Kommoss, Barbara Schmalfeldt, Jalid Sehouli, Annette Hasenburg, Marco Johannes Battista

Summary: This study investigated the clinical management of patients with pelvic high-grade serous carcinoma (HGSC) and its precursor lesion serous tubal intraepithelial carcinoma (STIC) in Germany. The survey showed significant inconsistency in the management of STIC patients, highlighting the need for prospective research to clarify the clinical impact of STIC lesions and their management.

ARCHIVES OF GYNECOLOGY AND OBSTETRICS (2023)

Add to Collection

Article Obstetrics & Gynecology

Vaccination strategies in breast cancer

Marcus Schmidt

Summary: This article discusses the principles and evidence for vaccination strategies in breast cancer, highlighting their potential to improve patient survival.

GYNAKOLOGIE (2023)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

Assessing breast density using the chemical-shift encoding-based proton density fat fraction in 3-T MRI

Tabea Borde, Mingming Wu, Stefan Ruschke, Christof Boehm, Jonathan Stelter, Kilian Weiss, Stephan Metz, Marcus Richard Makowski, Dimitrios C. C. Karampinos, Eva Maria Fallenberg

Summary: This study aims to establish proton density fat fraction (PDFF) as a quantitative biomarker for fat tissue concentration in breast MRI and correlate it with mammography. The results showed a negative correlation between PDFF and breast density measurements, and the proposed PDFF method could be easily incorporated into clinical routine breast MRI exams.

EUROPEAN RADIOLOGY (2023)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.